Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

BACKGROUND: The effect of combined insulin and dipeptidyl peptidase-4 inhibitor (DPP4i) therapy on major adverse cardiovascular events (MACEs) in patients with diabetic foot is unclear. METHODS: We conducted this nationwide cohort study using longitudinal claims data obtained from the Taiwan Nationa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yi-Hsuan, Huang, Yu-Yao, Wu, Yi-Ling, Lin, Cheng-Wei, Chen, Pei-Chun, Chang, Chee Jen, Hsieh, Sheng-Hwu, Sun, Jui-Hung, Chen, Szu-Tah, Lin, Chia-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192159/
https://www.ncbi.nlm.nih.gov/pubmed/30349614
http://dx.doi.org/10.1186/s13098-018-0378-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192159/
https://www.ncbi.nlm.nih.gov/pubmed/30349614
http://dx.doi.org/10.1186/s13098-018-0378-6

Ejemplares similares